SHANGHAI, March 19, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. ('Fangzhou” or the 'Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, reported its 2025 annual results, posting strong revenue growth and achieving full-year profitability, as its AI-enabled chronic disease management model continues to scale. Total revenue rose 30.2% year on year to RMB 3.53 billion in 2025, driven by steady growth in its consumer-facing businesses, including comprehensive medical services and online retail pharmacy services, which collectively grew by approximately 30%. The Company also recorded net profit of RMB 12 million, exceeding market expectations and marking a turnaround from a net loss in 2024. Adjusted net profit was up 19%, reaching RMB 20.4 million. This strong performance reflects continued momentum in Fangzhou’s core businesses and validates the effectiveness of the strong doctor-patient relationship model that underpins its chronic care platform.
Fangzhou Reports Robust 2025 Financial Results, Boosted by AI Chronic Care Strategy
